Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness.
Oncoimmunology
; 3(12): e955337, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25964861
ABSTRACT
Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor microenvironment, unleashing accumulation of tumor-associated macrophages that sustains tumor growth. This discovery extends our understanding on the role of inflammatory chemokines in tumor biology and provides rationale for their therapeutic targeting.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncoimmunology
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Itália